MV Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $242K | Sell |
10,065
-1,445
| -13% | -$37.8K | 0.02% | 182 |
|
|
2026
Q1 | $323K | Sell |
11,510
-3
| -0% | -$80 | 0.03% | 155 |
|
|
2025
Q4 | $287K | Buy |
11,513
+1,503
| +15% | +$37.9K | 0.03% | 158 |
|
|
2025
Q3 | $255K | Buy |
10,010
+1,354
| +16% | +$33.4K | 0.02% | 163 |
|
|
2025
Q2 | $210K | Buy |
8,656
+3,753
| +77% | +$87.5K | 0.02% | 173 |
|
|
2025
Q1 | $124K | Sell |
4,903
-1,786
| -27% | -$46.7K | 0.01% | 215 |
|
|
2024
Q4 | $177K | Sell |
6,689
-565
| -8% | -$15.3K | 0.02% | 179 |
|
|
2024
Q3 | $210K | Buy |
7,254
+414
| +6% | +$12.1K | 0.02% | 171 |
|
|
2024
Q2 | $191K | Buy |
6,840
+1,060
| +18% | +$29.2K | 0.02% | 174 |
|
|
2024
Q1 | $160K | Sell |
5,780
-21,181
| -79% | -$588K | 0.02% | 186 |
|
|
2023
Q4 | $776K | Sell |
26,961
-26,283
| -49% | -$795K | 0.1% | 95 |
|
|
2023
Q3 | $1.77M | Buy |
53,244
+592
| +1% | +$20.9K | 0.24% | 66 |
|
|
2023
Q2 | $1.93M | Buy |
52,652
+3,416
| +7% | +$133K | 0.26% | 56 |
|
|
2023
Q1 | $2.01M | Buy |
49,236
+187
| +0.4% | +$8.08K | 0.28% | 55 |
|
|
2022
Q4 | $2.51M | Buy |
49,049
+1,514
| +3% | +$72.6K | 0.39% | 40 |
|
|
2022
Q3 | $2.08M | Buy |
47,535
+1,662
| +4% | +$80.8K | 0.36% | 41 |
|
|
2022
Q2 | $2.4M | Buy |
45,873
+782
| +2% | +$39.9K | 0.41% | 40 |
|
|
2022
Q1 | $2.33M | Buy |
45,091
+291
| +0.6% | +$15.1K | 0.35% | 50 |
|
|
2021
Q4 | $2.65M | Buy |
44,800
+1,386
| +3% | +$68.7K | 0.38% | 44 |
|
|
2021
Q3 | $1.87M | Buy |
43,414
+2,468
| +6% | +$109K | 0.31% | 60 |
|
|
2021
Q2 | $1.6M | Buy |
40,946
+1,910
| +5% | +$74.3K | 0.27% | 64 |
|
|
2021
Q1 | $1.41M | Buy |
39,036
+7,887
| +25% | +$280K | 0.26% | 63 |
|
|
2020
Q4 | $1.15M | Buy |
31,149
+2,902
| +10% | +$106K | 0.22% | 61 |
|
|
2020
Q3 | $984K | Buy |
28,247
+4,520
| +19% | +$158K | 0.2% | 50 |
|
|
2020
Q2 | $736K | Buy |
23,727
+5,865
| +33% | +$199K | 0.17% | 56 |
|
|
2020
Q1 | $553K | Buy |
17,862
+3,970
| +29% | +$135K | 0.14% | 56 |
|
|
2019
Q4 | $516K | Buy |
13,892
+2,663
| +24% | +$94.9K | 0.11% | 76 |
|
|
2019
Q3 | $383K | Buy |
11,229
+954
| +9% | +$34.7K | 0.09% | 83 |
|
|
2019
Q2 | $422K | Buy |
10,275
+998
| +11% | +$39.6K | 0.1% | 75 |
|
|
2019
Q1 | $374K | Sell |
9,277
-411
| -4% | -$16.5K | 0.09% | 73 |
|
|
2018
Q4 | $401K | Buy |
9,688
+572
| +6% | +$23.7K | 0.11% | 65 |
|
|
2018
Q3 | $381K | Sell |
9,116
-811
| -8% | -$31.2K | 0.09% | 67 |
|
|
2018
Q2 | $342K | Buy |
9,927
+31
| +0.3% | +$1.06K | 0.09% | 70 |
|
|
2018
Q1 | $333K | Buy |
9,896
+2,260
| +30% | +$77.7K | 0.09% | 68 |
|
|
2017
Q4 | $262K | Sell |
7,636
-72
| -0.9% | -$2.46K | 0.07% | 78 |
|
|
2017
Q3 | $261K | Sell |
7,708
-580
| -7% | -$18.6K | 0.07% | 78 |
|
|
2017
Q2 | $264K | Buy |
8,288
+225
| +3% | +$7.1K | 0.08% | 78 |
|
|
2017
Q1 | $262K | Sell |
8,063
-187
| -2% | -$5.9K | 0.08% | 77 |
|
|
2016
Q4 | $254K | Sell |
8,250
-411
| -5% | -$12.5K | 0.09% | 76 |
|
|
2016
Q3 | $278K | Sell |
8,661
-1,127
| -12% | -$37.7K | 0.1% | 68 |
|
|
2016
Q2 | $327K | Buy |
9,788
+492
| +5% | +$15.7K | 0.12% | 67 |
|
|
2016
Q1 | $261K | Buy |
9,296
+1,370
| +17% | +$39.1K | 0.11% | 74 |
|
|
2015
Q4 | $243K | Buy |
7,926
+2,686
| +51% | +$84.5K | 0.1% | 84 |
|
|
2015
Q3 | $156K | Buy |
5,240
+827
| +19% | +$26.5K | 0.07% | 87 |
|
|
2015
Q2 | $140K | Sell |
4,413
-1,180
| -21% | -$38.5K | 0.06% | 99 |
|
|
2015
Q1 | $185K | Sell |
5,593
-1,147
| -17% | -$36.5K | 0.08% | 75 |
|
|
2014
Q4 | $199K | Buy |
+6,740
| New | +$193K | 0.09% | 70 |
|
Other funds holding PFE
MV Capital Management's PFE Position: Q2 2026 in Review
MV Capital Management reduced its Pfizer (PFE) stake by 13% in Q2 2026, selling an estimated $37.8K and leaving 10,065 shares worth $242K. The position accounts for 0.02% of the portfolio, ranked #182.
MV Capital Management first reported a position in PFE in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.65M in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- MV Capital Management held 10,065 shares of Pfizer worth $242K as of Q2 2026.
- MV Capital Management sold 1,445 Pfizer shares in Q2 2026, an estimated $37.8K.
- Pfizer made up 0.02% of MV Capital Management's portfolio in Q2 2026, its #182 holding.
- MV Capital Management first reported a position in Pfizer in Q4 2014 and has held it in 47 quarters since.
- MV Capital Management's Pfizer position peaked at $2.65M in Q4 2021.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on MV Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.